GLP-1 products and trial candidates.
Six selected formulations and candidates, not the complete GLP-1 pipeline. US label information and sponsor trial reports are different source types. This is not an efficacy comparison or prescribing guide.
Source snapshot: 2026-08-30. Figure version: 2026-08-30.1.
Table and explanation: https://stemcellatlas.com/en/quiz/new-glp-1-comparison
Figure: https://stemcellatlas.com/en/data/longevity-comparisons#glp-1-products
Sources:
https://investor.lilly.com/node/54321/pdf
https://pi.lilly.com/us/zepbound-uspi.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501